干扰素治疗慢性病毒性肝炎的不良反应及护理

干扰素(Interferon,IFN)是公认的治疗慢性肝炎的重要药物。但是,干扰素在使用的过程中存在较多的不良反应。本文综述了干扰素应用过程中可能出现的不良反应及护理。     

干扰素治疗慢性病毒性肝炎副作用的观察及护理

1995年11月一1997年12月,我科用干扰素治疗60例慢性病毒性肝炎患者,现将观察到的副反应报道如下。l资料与方法11临床资料60例患者中男引例,女9例,年龄门一63岁。其中乙型肝炎42例,丙型肝炎12例,乙型肝炎重叠丙型肝炎6例。病程l－16年。治疗前和治疗后每隔1个月均作肝功能各项生化指标及血常规与血小板等检查。12治疗方法采用基因重组干扰素a．fo（赛洛金）3－5MU治疗,用注射用水lml溶解后,作臀部肌肉注射,每周3次,6个月为1疗程。13观察结果分为两个不同剂量组,引例用重组干扰素a．fo3MU冶疗,有1例因白细胞减少至2．5X10’／L…     

干扰素治疗小儿慢性乙型病毒性肝炎的护理

总结25例小儿乙型病毒性肝炎患儿行干扰素抗病毒治疗的护理,强调应加强治疗前的心理护理及治疗后不良反应的护理。     

干扰素治疗慢性病毒性肝炎副作用的观察及护理

观察了接受干扰素治疗的慢性病毒性肝炎４３例，发现发热、流感样症状、神经精神症状、消化道反应、骨髓抑制、一过性肝损害是干扰素常见的副作用。因此，在使用干扰素治疗病毒性肝炎的过程中，应重视药物的副作用，并采取相应的护理措施     

干扰素治疗慢性病毒性肝炎严重不良反应的观察和护理

正干扰素是治疗慢性乙型肝炎或慢性丙型肝炎常用临床方案,它具有抗病毒、调节免疫、抗肿瘤及减缓肝纤维化作用,显著提高了病人疗效[1]。但干扰素不良反应多,常见不良反应如流感样症状、血细胞减少、全身酸痛、转氨酶升高、食欲下降、体重减轻等,病人可以耐受,少见的严重不良反应导致治疗终止,病情恶化。我科2008年1月—2012年12月用干扰素治疗病毒性肝炎病人626例,对其中27例严重不良反应观察及护理总结。现报告如下。     

干扰素治疗病毒性肝炎现状

干扰素(IFN)是强力抗病毒、抗增殖和具免疫调节作用的生物性物质，在抗病毒治疗中起着重要作用。近年来用干扰素治疗乙型、丙型病毒性肝炎已日趋普遍，经近年来国内、外临床应用，获得治疗经验。干扰素虽非治疗乙、丙型肝炎理想药物，但仍是唯一有效药物。本就其临床应用作一综述。     

干扰素治疗病毒性肝炎出现精神抑郁症状的护理干预

干扰素目前已广泛应用于病毒性肝炎的治疗中,由于该药治疗时间长,不良反应多,需要联合临床观察进行用药,在诸多不良反应中病人出现精神抑郁不仅影响病人身心健康,也存在安全隐患,如何避免不良事件发生,保证病人安全、正常用药,主要从以下几方面采取护理措施.     

干扰素治疗病毒性肝炎诱发甲亢2例

例 1 ,男 ,39岁 ,多汗 ,消瘦 2个月。 1 996年体检发现肝功能异常。丙氨酸转氨酶及天门氨冬转氨酶轻度升高 ,在本院就诊用保肝药治疗 ,疗效欠佳 ,5年前曾因“十二指肠球部溃疡并上消化道出血”用过“人冻干血浆” ,查体未见异常 ,检验抗 ＨＣＶ阳性 ,诊断为慢性丙型肝炎 ,转上级医院给予干扰素治疗 ,30 0Ｕ隔日 1次肌注 ,1个月后减为每周 2次 ,疗程半年 ,肝功能基本恢复正常。停药半年后 ,患者出现消瘦、乏力、多汗、心悸 ,体重下降 1 0余公斤 ,大便次数增多 ;查体 :无眼突 ,甲状腺无明显肿大 ,心率 1 0 8次 /ｍｉｎ ,双肺未见异常 ,腹平软…     

慢性丙型病毒性肝炎患者干扰素治疗后干扰素抗体的表达水平及其临床意义

目的：探讨慢性丙型病毒性肝炎（丙肝）患者干扰素治疗后干扰抗体的表达水平及其对干扰素治疗影响。方法：选择94例慢性丙肝患者采用a2b-IFN治疗，剂量为300mU/次，每周3次，3个月为1个疗程，共3个疗程，动态检测抗－HCV，HCV－RNA及a2b-IFN-IgG表达水平。结果a2b-IFN治疗后抗－HCV，HCV－RNA阴转率分别为32．98％（31／94）和38．30（36／94），常规治疗组治疗后抗－HCV，HCV0－RNA阴转率分别为10．00％（4／40）和15．00％（6／40），两者相比有显著性差异（P＜0．01），干扰素治疗后抗－IFN－IgG阳检率为5．32％（5／94），与常规治疗组相比无显著性差异（P＞0．05），其中第一，第二，第三疗程结束后，抗－IFN－IgG阳检率分别为0（0／94），2．13％（2／94）和5．32％（5／94），干扰素治疗中抗－IFN－IgG产生率无显著性差异（P＞0．05），结论：a2b－IFN对抗－HCV，HCV－RNA阴转具有肯定疗效，且优于常规治疗，其具有一定的免疫原性，在治疗过程中可诱导机体产生少量抗a2b-IFN-IgG，其对IFN－a2b的抑制作用较弱。     

干扰素治疗慢性乙型病毒性肝炎68例疗效分析

乙型肝炎病毒的持续存在是慢性乙肝反复发作的根本原因,因此有效的抗病毒治疗是根治乙肝的关键。我院于2002年6月-2005年2月应用国产干扰素治疗慢性乙肝,取得了一定的疗效,现报道如下。1对象和方法1.1病例选择2002年6月~2005年2月在我院诊为慢性乙型病毒性肝炎病人118例,诊断符     

Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection

BACKGROUND: Interferon (IFN)-resistant hepatitis C virus strains limit efficacy of antiviral combination therapy in patients infected with genotypes 1 and 4. A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Our aim was to investigate this approach in genotype 4 patients. METHODS: Viral load was measured in 46 patients before and 24 h after 10 megaunits (MU) IFN-alpha2b, and before and during 2 weeks of daily 5 MU IFN-alpha2b administration. Thereafter, patients received 48 weeks combination therapy with either 180 microg PEG-IFN-alpha2a/week (n=33), 1.5 microg/kg PEG-IFN-alpha2b/week (n=7) or 5 MU IFN-alpha2b/2 days (n=6), along with 1-1.2g RBV/day. For prediction analysis the largest group (PEG-IFN-alpha2a) was evaluated only. RESULTS: Median 24 h log10 change after 10 MU IFN-alpha2b was 1.15 (range 0.08-2.48) and after 5 MU IFN-alpha2b was 0.81 (-0.12-2.22; P<0.0001). Log10 changes after 2 weeks on 5 MU IFN-alpha2b daily and 24 h after 10 MU were the best predictors of early virological response (defined by negativity of a standard qualitative PCR) to PEG-IFN-alpha2a/RBV combination therapy (area under curve [AUC]=0.97; P<0.001, receiver operating characteristics), 24 h log10 change after 10 MU was the best predictor of sustained virological response (SVR; AUC=0.91, P=0.001). CONCLUSION: As in genotype 1 patients, there is large variation in IFN responsiveness, including the presence of resistant strains, in genotype 4 patients. A 24 h log10 change after 10 MU IFN-alpha2b is an excellent predictor of SVR on PEG-IFNalpha2a/RBV combination therapy. This test may be useful to obtain homogeneous groups for clinical studies and could help in clinical decision making.     

Nursing care of patients with viral hepatitis.

The nurse's role in the care of clients with acute viral hepatitis is based upon a nursing assessment of the client and his family system, diagnosis and planning for the individual needs of the client, and anticipatory guidance related to the client's return to the family and community.     

Problems in the treatment of hepatitis C with interferon.

A marked increase in the rate of eradication of hepatitis C virus (HCV) has been achieved by the combination of interferon-alpha2b and ribavirin when compared with interferon-alpha2b alone. However, even with combination therapy, hepatitis persists in more than half of the patients with chronic herpatitis C and progresses to liver cirrhosis and hepatocellular carcinoma with time. What needs to be kept in mind is that, whether by its natural course or by therapy to suppress liver inflammation or by interferon therapy, the rate of development of hepatocellular carcinoma is reduced if ALT is maintained at low levels. Attention should therefore be focused on the development of drugs which enhance the effect of interferon as well as drugs which suppress liver inflammation.     

Interferon in the treatment of acute viral hepatitis B

The Soviet leukocytic alpha 2-interferon obtained by gene engineering was assessed (according to the clinical and biochemical findings) for the therapeutic efficacy in acute viral hepatitis B. The drug was injected intramuscularly to patients with grave and medium-grave hepatitis during 10 days. The treatment was instituted within the first 1-5 days of jaundice. The patients with medium-grave acute viral hepatitis B manifested a beneficial therapeutic effect of alpha 2-interferon obtained by gene engineering as did the patients with the grave disease pattern before they developed the signs of liver encephalopathy.